Under the agreement iECURE plans to advance Precision's PBGENE-PCSK9 candidate into Phase 1 studies and gain access to Precision's PCSK9-directed ARCUS nuclease to develop additional gene-editing ...

FARMINGDALE, N.Y. - December 5, 2018 - Precision Label Corporation, a New York-based converter serving major cosmetic brands, is expanding its digital production capabilities with the addition of ...

DURHAM – Precision Biosciences has inked a deal with gene editing company iECURE to advance one of Precision’s drug candidates into Phase 1 clinical studies. The agreement also gives iECURE a license ...

Precision BioSciences, Inc. DTIL announced that it has entered into an exclusive license agreement with New York-based Tiziana Life Sciences plc TLSA to develop the latter’s fully human anti-CD3 ...

As fellow gene editing firm Crispr Therapeutics AG hosted an innovation day in which it confirmed plans for regulatory filings by year-end for an ex vivo gene editing therapy in sickle cell disease ...